论文部分内容阅读
本文报道良性或潜在恶性室性心律失常患者口服或静脉应用英地卡胺(Indecainide)的短程疗效和长期随访结果。方法:短程静脉试验10例,室性早搏次数每小时≥30次或非持续性室速。静滴本品,初3天每日60～100 mg(每分钟12.5～15μg/kg),以后根据治疗反应调整剂量,极量每日400 mg。短程口服试验20例(其中8例为短程静脉试验患者,12例为新病人),口服本品50mg每8小时1次,根据治疗反应逐渐增至75或100 mg每8小时1次。当PR间期>0.28秒、QRS>0.15秒或QTc间
This article reports the short-term efficacy and long-term follow-up of oral or intravenous use of Indecainide in patients with benign or potentially malignant ventricular arrhythmias. Methods: Short-range venous test in 10 cases, the number of ventricular premature beats ≥30 times per hour or non-sustained ventricular tachycardia. Intravenous infusion of this product, the first three days daily 60 ~ 100 mg (12.5 ~ 15μg / kg per minute), after the dose adjusted according to the treatment response, the maximum daily dose of 400 mg. Short-term oral test of 20 cases (of which 8 cases of short-range venous test patients, 12 cases of new patients), oral administration of this product 50mg every 8 hours 1, according to the response to treatment gradually increased to 75 or 100 mg once every 8 hours. When the PR interval> 0.28 seconds, QRS> 0.15 seconds or between QTc